Illumina (NASDAQ:ILMN) Director Keith Meister Sells 119,501 Shares

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 119,501 shares of the company’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $218.40, for a total transaction of $26,099,018.40. Following the completion of the transaction, the director directly owned 770,350 shares in the company, valued at approximately $168,244,440. The trade was a 13.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Illumina Price Performance

Shares of ILMN stock traded down $3.44 on Friday, reaching $218.22. The company’s stock had a trading volume of 1,728,019 shares, compared to its average volume of 1,904,505. The company has a market capitalization of $32.95 billion, a P/E ratio of 40.71, a PEG ratio of 3.02 and a beta of 1.46. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $231.81. The stock’s 50 day simple moving average is $197.58 and its 200-day simple moving average is $158.61. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm’s revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the business earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities analysts predict that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Argus raised its price target for Illumina (ILMN) from $180 to $235 and upgraded the stock to “buy,” implying additional upside from recent levels. The bullish view reflects confidence in Illumina’s earnings outlook and continued demand for genomic sequencing.
• Neutral Sentiment: Broader biotechnology coverage was mixed. 10x Genomics’ strong rally, supported by consumables growth and improved guidance, highlights investor interest in life-sciences tools, although weak instrument demand and valuation concerns remain sector risks. 10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
• Neutral Sentiment: Articles about robotics and AI-focused ETFs may support long-term interest in technology and automation themes, but they do not represent a direct catalyst for Illumina’s business or stock. Are Robots the New Normal? Bet on these ETFs to Invest in the Future
• Negative Sentiment: Zacks Research downgraded ILMN from “strong buy” to “hold.” The change introduces caution after the stock’s substantial advance and suggests that current valuation and expectations may leave less room for execution missteps. Illumina Analyst Downgrade
• Negative Sentiment: PacBio’s reduced 2026 outlook, attributed to weaker instrument demand and slower clinical adoption, is a modest negative read-through for the sequencing market. Although PacBio is a competitor rather than an Illumina subsidiary, the update raises questions about the pace of demand across the industry. PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test

Institutional Trading of Illumina

A number of hedge funds have recently bought and sold shares of ILMN. Elyxium Wealth LLC purchased a new position in shares of Illumina during the fourth quarter worth approximately $25,000. Fiduciary Financial Advisors bought a new stake in shares of Illumina in the 2nd quarter worth approximately $26,000. Keating Financial Advisory Services Inc. purchased a new stake in shares of Illumina in the 2nd quarter valued at $32,000. Quarry LP purchased a new stake in shares of Illumina in the 3rd quarter valued at $32,000. Finally, Nano Cap New Millennium Growth Fund L P bought a new position in shares of Illumina during the 4th quarter valued at $33,000. Institutional investors own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Evercore restated an “outperform” rating on shares of Illumina in a research report on Monday, July 6th. Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price for the company in a research report on Thursday, May 14th. Canaccord Genuity Group boosted their price target on shares of Illumina from $190.00 to $205.00 and gave the stock a “hold” rating in a research note on Monday, August 3rd. Deutsche Bank Aktiengesellschaft lowered shares of Illumina to a “hold” rating in a report on Wednesday, August 5th. Finally, Wall Street Zen upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Nine analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Illumina currently has a consensus rating of “Hold” and a consensus target price of $191.31.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.